Logo image of MIST

MILESTONE PHARMACEUTICALS IN (MIST) Stock Fundamental Analysis

NASDAQ:MIST - Nasdaq - CA59935V1076 - Common Stock - Currency: USD

0.8889  +0.07 (+8.8%)

After market: 0.871 -0.02 (-2.01%)

Fundamental Rating

1

MIST gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 197 industry peers in the Pharmaceuticals industry. MIST has a bad profitability rating. Also its financial health evaluation is rather negative. MIST is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year MIST has reported negative net income.
MIST had a negative operating cash flow in the past year.
MIST had negative earnings in each of the past 5 years.
MIST had a negative operating cash flow in each of the past 5 years.
MIST Yearly Net Income VS EBIT VS OCF VS FCFMIST Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

With a Return On Assets value of -54.99%, MIST is not doing good in the industry: 62.94% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -315.81%, MIST is doing worse than 73.60% of the companies in the same industry.
Industry RankSector Rank
ROA -54.99%
ROE -315.81%
ROIC N/A
ROA(3y)-70.9%
ROA(5y)-56.36%
ROE(3y)-253.25%
ROE(5y)-166.55%
ROIC(3y)N/A
ROIC(5y)N/A
MIST Yearly ROA, ROE, ROICMIST Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MIST so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MIST Yearly Profit, Operating, Gross MarginsMIST Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K

More info and screens

3

2. Health

2.1 Basic Checks

MIST does not have a ROIC to compare to the WACC, probably because it is not profitable.
MIST has more shares outstanding than it did 1 year ago.
MIST has more shares outstanding than it did 5 years ago.
MIST has a worse debt/assets ratio than last year.
MIST Yearly Shares OutstandingMIST Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
MIST Yearly Total Debt VS Total AssetsMIST Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

MIST has an Altman-Z score of -6.17. This is a bad value and indicates that MIST is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -6.17, MIST is doing worse than 65.99% of the companies in the same industry.
MIST has a Debt/Equity ratio of 4.06. This is a high value indicating a heavy dependency on external financing.
MIST's Debt to Equity ratio of 4.06 is on the low side compared to the rest of the industry. MIST is outperformed by 83.76% of its industry peers.
Industry RankSector Rank
Debt/Equity 4.06
Debt/FCF N/A
Altman-Z -6.17
ROIC/WACCN/A
WACC8.32%
MIST Yearly LT Debt VS Equity VS FCFMIST Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 9.10 indicates that MIST has no problem at all paying its short term obligations.
The Current ratio of MIST (9.10) is better than 81.22% of its industry peers.
MIST has a Quick Ratio of 9.10. This indicates that MIST is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 9.10, MIST belongs to the top of the industry, outperforming 81.73% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.1
Quick Ratio 9.1
MIST Yearly Current Assets VS Current LiabilitesMIST Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

More info and screens

0

3. Growth

3.1 Past

MIST shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 50.43%, which is quite impressive.
The Revenue for MIST has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)50.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.81%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

MIST is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -29.18% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-88.75%
EPS Next 2Y-43.45%
EPS Next 3Y-5.8%
EPS Next 5Y-29.18%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MIST Yearly Revenue VS EstimatesMIST Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
MIST Yearly EPS VS EstimatesMIST Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MIST reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year MIST is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MIST Price Earnings VS Forward Price EarningsMIST Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MIST Per share dataMIST EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

MIST's earnings are expected to decrease with -5.80% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-43.45%
EPS Next 3Y-5.8%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MIST!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MILESTONE PHARMACEUTICALS IN

NASDAQ:MIST (4/17/2025, 8:00:00 PM)

After market: 0.871 -0.02 (-2.01%)

0.8889

+0.07 (+8.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-13 2025-03-13/bmo
Earnings (Next)05-12 2025-05-12/bmo
Inst Owners42.61%
Inst Owner Change0%
Ins Owners0.66%
Ins Owner Change0%
Market Cap47.42M
Analysts80
Price Target9.95 (1019.36%)
Short Float %1.46%
Short Ratio0.7
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.98%
Min EPS beat(2)-27.93%
Max EPS beat(2)15.96%
EPS beat(4)3
Avg EPS beat(4)9.15%
Min EPS beat(4)-27.93%
Max EPS beat(4)27.76%
EPS beat(8)6
Avg EPS beat(8)8.27%
EPS beat(12)9
Avg EPS beat(12)8.72%
EPS beat(16)12
Avg EPS beat(16)14.24%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.88%
PT rev (3m)-4.88%
EPS NQ rev (1m)8.64%
EPS NQ rev (3m)7.5%
EPS NY rev (1m)-27.18%
EPS NY rev (3m)-36%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-100%
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.61
P/tB 3.61
EV/EBITDA N/A
EPS(TTM)-0.69
EYN/A
EPS(NY)-1.3
Fwd EYN/A
FCF(TTM)-0.54
FCFYN/A
OCF(TTM)-0.54
OCFYN/A
SpS0
BVpS0.25
TBVpS0.25
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -54.99%
ROE -315.81%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-70.9%
ROA(5y)-56.36%
ROE(3y)-253.25%
ROE(5y)-166.55%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 4.06
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 31.43%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.1
Quick Ratio 9.1
Altman-Z -6.17
F-Score2
WACC8.32%
ROIC/WACCN/A
Cap/Depr(3y)151.06%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.81%
EPS Next Y-88.75%
EPS Next 2Y-43.45%
EPS Next 3Y-5.8%
EPS Next 5Y-29.18%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y31.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year50.27%
EBIT Next 3Y-12.79%
EBIT Next 5Y29.19%
FCF growth 1Y37.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y37.86%
OCF growth 3YN/A
OCF growth 5YN/A